Glenmark gets US FDA nod for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg

Glenmark Pharmaceuticals, USA has received final approval by the United States Food & Drug Administration (US FDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla Capsules, of Allergan Pharmaceuticals International.

According to IQVIA sales data for the 12 month period ending May 2022, the Taytulla Capsules market achieved annual sales of approximately $85.9 million*.

Glenmark’s current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 ANDAs pending approval with the US FDA.